

Leticia Leon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1025158/publications.pdf>

Version: 2024-02-01

45
papers

874
citations

516215

16
h-index

500791

28
g-index

49
all docs

49
docs citations

49
times ranked

1677
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases" by Aydın et al. Annals of the Rheumatic Diseases, 2023, 82, e70-e70.	0.5	3
2	Impact of rheumatoid arthritis on sexuality: adaptation and validation of the Qualisex questionnaire for use in Spain. Rheumatology International, 2022, 42, 1819-1829.	1.5	5
3	Persistent post-discharge symptoms after COVID-19 in rheumatic and musculoskeletal diseases. Rheumatology Advances in Practice, 2022, 6, rkac008.	0.3	12
4	Mortality related to COVID-19 in patients with rheumatic and musculoskeletal diseases, first wave of the outbreak: a single-center study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210902.	1.2	2
5	Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2096269.	1.2	20
6	Mortality rate in rheumatoid arthritis-related interstitial lung disease: the role of radiographic patterns. BMC Pulmonary Medicine, 2021, 21, 205.	0.8	15
7	Factors Associated with Health-Related Quality of Life in Psoriatic Arthritis Patients: A Longitudinal Analysis. Rheumatology and Therapy, 2021, 8, 1341-1354.	1.1	4
8	Development of the Anxiety, Depression and Coping (ADAF) screening tool for emotional and coping problems in cancer patients. Psycho-Oncology, 2021, 30, 1894-1901.	1.0	1
9	Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases. Pediatric Rheumatology, 2021, 19, 162.	0.9	11
10	Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases, 2020, 79, 1393-1399.	0.5	110
11	Response to: "Correspondence on "Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases" by Schulze-Koops et al. Annals of the Rheumatic Diseases, 2020, , annrhumdis-2020-219230.	0.5	1
12	Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. Rheumatology, 2020, 59, 2099-2108.	0.9	48
13	Comment on: Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry: reply. Rheumatology, 2020, 59, 2181-2182.	0.9	1
14	Emotional regulation processes: influence on pain and disability in fibromyalgia patients. Clinical and Experimental Rheumatology, 2020, 38 Suppl 123, 40-46.	0.4	1
15	Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1987800.	1.2	7
16	Contribution of the bone and cartilage/soft tissue components of the joint damage to the level of disability in rheumatoid arthritis patients: a longitudinal study. Clinical Rheumatology, 2019, 38, 691-700.	1.0	16
17	Validation of a Quality of Life Instrument in Spanish Patients With Rheumatic Diseases. Journal of Clinical Rheumatology, 2019, 25, 78-84.	0.5	5
18	Direct medical costs and their predictors in the EMAR-II cohort: "Variability in the management of rheumatoid arthritis and spondyloarthritis in Spain" Reumatología Clínica (English Edition), 2018, 14, 4-8.	0.2	3

#	ARTICLE	IF	CITATIONS
19	Costes mdicos directos y sus predictores en la cohorte â€œVariabilidad en el manejo de la artritis reumatoide y las espondiloartritis en Espaaâ€. Reumatologa Clnica, 2018, 14, 4-8.	0.2	6
20	Recomendaciones para el manejo de la comorbilidad en la prctica clnica en pacientes con espondiloartritis axial. Reumatologa Clnica, 2018, 14, 346-359.	0.2	7
21	Expert recommendations on the psychological needs of patients with rheumatoid arthritis. Rheumatology International, 2018, 38, 2167-2182.	1.5	12
22	Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clinical and Experimental Rheumatology, 2018, 36, 29-35.	0.4	15
23	Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 121-128.	0.4	6
24	Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice. Clinical and Experimental Rheumatology, 2018, 36, 173.	0.4	1
25	EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Annals of the Rheumatic Diseases, 2017, 76, 639-646.	0.5	157
26	A bibliometric study of the scientific publications on patient-reported outcomes in rheumatology. Seminars in Arthritis and Rheumatism, 2017, 46, 828-833.	1.6	19
27	Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach. Scientific Reports, 2017, 7, 10189.	1.6	50
28	Transitional care for rheumatic conditions in Europe: current clinical practice and available resources. Pediatric Rheumatology, 2017, 15, 49.	0.9	39
29	Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 165-170.	0.4	2
30	Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scandinavian Journal of Rheumatology, 2016, 45, 456-460.	0.6	30
31	Influence of patient personality in the treatment of rheumatoid arthritis. Rheumatology International, 2016, 36, 1549-1555.	1.5	6
32	Systematic review and critical appraisal of transitional care programmes in rheumatology. Seminars in Arthritis and Rheumatism, 2016, 46, 372-379.	1.6	58
33	Influence of demographic and clinical factors on the mortality rate of a rheumatoid arthritis cohort: A 20-year survival study. Seminars in Arthritis and Rheumatism, 2016, 45, 533-538.	1.6	18
34	Dose down-titration of biological DMARDs in patients with rheumatoid arthritis over time and in daily clinical practice. Clinical and Experimental Rheumatology, 2016, 34, 872-879.	0.4	2
35	Treatment in rheumatoid arthritis and mortality risk in clinical practice: the role of biologic agents. Clinical and Experimental Rheumatology, 2016, 34, 1026-1032.	0.4	3
36	Incidence of Physical Disability Related to Musculoskeletal Disorders in the Elderly: Results From a Primary Careâ€Based Registry. Arthritis Care and Research, 2015, 67, 89-93.	1.5	8

#	ARTICLE	IF	CITATIONS
37	Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 506-513.	1.6	20
38	An early intervention program for subacute physical disability related to musculoskeletal diseases in the elderly: a pilot study. <i>Rheumatology International</i> , 2015, 35, 1183-1191.	1.5	1
39	Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 559-69.	0.4	31
40	Negative affect in systemic sclerosis. <i>Rheumatology International</i> , 2014, 34, 597-604.	1.5	13
41	Health-related quality of life as a main determinant of access to rheumatologic care. <i>Rheumatology International</i> , 2013, 33, 1797-1804.	1.5	11
42	Weather conditions may worsen symptoms in rheumatoid arthritis patients: The possible effect of temperature. <i>Reumatologia Clínica</i> , 2013, 9, 226-228.	0.2	27
43	Orthopedic Surgery in Rheumatoid Arthritis in the Era of Biologic Therapy. <i>Journal of Rheumatology</i> , 2013, 40, 1850-1855.	1.0	23
44	Prognostic factors for long-term work disability due to musculoskeletal disorders. <i>Rheumatology International</i> , 2012, 32, 3831-3839.	1.5	20
45	Effectiveness of an early cognitive-behavioral treatment in patients with work disability due to musculoskeletal disorders. <i>Arthritis and Rheumatism</i> , 2009, 61, 996-1003.	6.7	19